|
Jul 9
|
Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term
|
|
Jul 9
|
Brokers Suggest Investing in Gilead (GILD): Read This Before Placing a Bet
|
|
Jul 9
|
Gilead Finalizes Agreement With the Global Fund to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries
|
|
Jul 8
|
Gilead Sciences Rallies 27.2% in Six Months: Buy or Sell the Stock?
|
|
Jul 8
|
Has Gilead Sciences (GILD) Outpaced Other Medical Stocks This Year?
|
|
Jul 1
|
Chronic Hepatitis B Market Analysis and Forecast, 2025-2035 | Diagnostic Advances, Innovative Therapies, and Rising Awareness Bolster Growth
|
|
Jun 30
|
Gilead extends gains after Supreme Court upheld an Obamacare provision
|
|
Jun 30
|
This firm represents one of investing’s toughest moral debates
|
|
Jun 28
|
Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer
|
|
Jun 27
|
Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know
|
|
Jun 27
|
Gilead, Exact Jump After The Supreme Court Upholds A 'Cornerstone' Of Health Care
|
|
Jun 27
|
Kymera’s partnerships with Sanofi and Gilead drive value
|
|
Jun 27
|
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
|
|
Jun 27
|
Debut Named to TIME's List of the TIME100 Most Influential Companies 2025
|
|
Jun 26
|
Northwell Health named to TIME100 Most Influential Companies 2025 list
|
|
Jun 26
|
Kymera weakness a buying opportunity, says Stifel
|
|
Jun 26
|
Morning Movers: General Mills dips following fourth quarter report
|
|
Jun 26
|
KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update
|
|
Jun 25
|
Gilead Sciences (GILD) Stock Moves -1.18%: What You Should Know
|
|
Jun 25
|
Alger Russell Innovation Index Updates for Second Quarter 2025
|